WILMINGTON, DE — AOP Health US has begun commercial use of Rapiblyk, an intravenous heart rhythm treatment approved by the U.S. Food and Drug Administration last year, as hospitals seek additional tools for managing critically ill cardiac patients in intensive care settings.
The company said the first U.S. patient was treated with the drug at The Valley Hospital in Paramus, NJ, marking the initial clinical deployment of the therapy following FDA approval in November 2024.
Rapiblyk, also known as landiolol, is an ultra-short-acting beta blocker used for rapid heart rate control in patients with supraventricular tachycardia, atrial fibrillation, and atrial flutter, particularly in perioperative and critical-care environments.
The therapy has previously been approved in Europe, Japan, and Canada.
The drug is administered intravenously in monitored hospital settings and is designed to provide rapid onset and offset of action, allowing physicians to adjust heart rate management quickly in unstable patients.
“Cardiac critical care teams require fast, precise tools to stabilize patients with complex and life-threatening conditions,” Yonathan Litwok, director of cardiac critical care at The Valley Hospital, said in a statement.
The launch gives AOP Health US an entry into the U.S. critical-care cardiovascular market, where hospitals continue to expand specialized treatment capabilities for patients requiring continuous cardiac monitoring and rapid intervention.
John Kimmet, general manager of AOP Health US, said the company views the launch as part of its broader U.S. expansion strategy focused on unmet needs in critical-care medicine.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.